| AKR1B10 is a redox/lipid-metabolism associated aldo-keto reductase that is frequently linked to tumor growth, survival, invasion, and therapy resistance, but its role is context-dependent rather than uniformly oncogenic in every cancer. In many cancers—notably lung, liver, pancreatic, and some breast settings—AKR1B10 is upregulated and tends to support malignant behavior by detoxifying reactive carbonyls, protecting membrane lipids, sustaining fatty-acid synthesis/lipid homeostasis, and helping cells tolerate oxidative stress. Those effects can reduce apoptosis and make tumor cells more drug-resistant. A key reason AKR1B10 matters in cancer is that it appears to sit at the intersection of oxidative stress defense, lipid handling, and resistance biology. Recent work also links AKR1B10 to ferroptosis suppression in at least some models, meaning higher AKR1B10 can help cancer cells avoid lipid-peroxidation-driven death; that has been tied to cisplatin resistance in gastric cancer and ferroptosis protection in triple-negative breast cancer models.
|